Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (45)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Tirelli, U.
Right arrow Articles by Gisselbrecht, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tirelli, U.
Right arrow Articles by Gisselbrecht, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 3:843-847, 1992
© 1992 European Society for Medical Oncology

research-article

Prospective study with combined low-dose chemotherapy and zidovudine in 37 patients with poor-prognosis AIDS-related non-Hodgkin's lymphoma

U. Tirelli1,, D. Errante1, E. Oksenhendler6, M. Spina1, E. Vaccher1, D. Serraino5, R. Gastaldi7, L. Repetto8, G. Rizzardini9, A. Carbone3, G. Bertola4, E Mandelli7, S. Monfardini2 and C. Gisselbrecht6

1Division of Medical Oncology and AIDS Program, Centro di Riferimento Oncologico (CRO)
2Division of Medical Oncology
3Division of Pathology
4Division of Oncologic Surgery
5Division of Epidemiology, C.R.O. Aviano, Italy
6Division of Hematology, Hopital S. Louis Paris, France
7Division of Hematology, Universit{acute} la Sapienza Roma
8Division of Medical Oncology, Istituto Scientifico Tumori Genova
9Division of Infectious Disease, Ospedale Sacco Milan, Italy

Dr. Umberto Tirelli Division of Medical Oncology and AIDS Program Centro di Riferimento Oncologico Via Pedemontana Occidentale 33081 Aviano, Italy

The French-Italian Cooperative Study Group included patients with poor-prognosis AIDS-related non-Hodgkin's lymphoma (NHL), defined as those with performance status (PS) ≥ 3 and /or opportunistic infections (OI), in a prospective study with a 50% reduced-dose combination chemotherapy regimen: CHVmP-Vincristine-bleo (cyclophosphamide 300 mg/m2 i.v. day 1, doxorubicin 25 mg/m2 i.v. day 1, teniposide 30 mg/m2 i.v. day 1, prednisone 20 mg/m2 per os days 1–5, vincristine 2 mg i.v. day 15, and bleomycin 10 mg i.v. day 15), given every 21 days for eight cycles, and concomitant zidovudine 500 mg per os per day. The aims of this combined treatment were to reduce bone marrow toxicity and infectious complications related to chemotherapy (with a low-dose chemotherapy regimen), and to control the HIV and related infectious complications (with zidovudine therapy). Thirty-seven patients entered this prospective study. At the time of the NHL diagnosis, 41% of the patients had asymptomatic HIV infection, 27% had ARC and 32% had already had CDC-defined diagnoses of AIDS. The median CD4+cell count was 35 mm3. Only 29 patients are evaluable for response, since 8 received only one cycle of chemotherapy. Fifteen of 29 (52%) patients obtained objective responses, with only 4 (14%) achieving complete remissions (CR) of 1, 4, 14 and 29+ months. Three (16%) CRs were achieved in 19 evaluable patients included in the study because of poor PS, and only one CR was observed in 10 evaluable patients with histories of OI, either alone or with poor PS. The most common side effect was bone marrow toxicity with 2 related toxic deaths. Of the 21 (72%) patients who received concomitant zidovudine treatment, only 12 (57%) were able to receive the drug during chemotherapy. The other 9 patients had to stop the anti-retroviral treatment due to hematological toxicity. Nine (43%) cases of OI were observed among the 21 patients who received zidovudine. Of the 16 patients who did not receive zidovudine, the reason in 13 instances was the presence of granulocytopenia at diagnosis of the NHL, and refusal of the drug in three. Five (31%) cases of OI were observed. In conclusion, this study revealed that patients with poor-prognosis AIDS-related NHL did not benefit from a combined low-dose chemotherapy regimen and concomitant zidovudine treatment. We obtained a lower CR rate than the ones in other published reports using conventional or low-dose chemotherapy. In addition, despite the low-dose chemotherapy regimen employed, we observed significant bone marrow toxicity with 2 deaths, and grades 3 and 4 leukopenia in 27 patients, and grades 3 or 4 thrombocytopenia in 11. Finally, the early application of zidovudine did not prevent a high (43%) incidence of OI during or immediately after treatment.

AIDS-related, chemotherapy, non-Hodgkin's, lymphoma, zidovudine


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 BloodHome page
N. Mounier, M. Spina, J. Gabarre, M. Raphael, G. Rizzardini, J.-B. Golfier, E. Vaccher, A. Carbone, B. Coiffier, G. Chichino, et al.
AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy
Blood, May 15, 2006; 107(10): 3832 - 3840.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. Tosi, F. Gherlinzoni, P. Mazza, G. Visani, O. Coronado, P. Costigliola, E. Raise, M. Mazzetti, F. Gritti, F. Chiodo, et al.
3'-Azido 3'-Deoxythymidine + Methotrexate as a Novel Antineoplastic Combination in the Treatment of Human Immunodeficiency Virus-Related Non-Hodgkin's Lymphomas
Blood, January 15, 1997; 89(2): 419 - 425.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
U. Tirelli, S. Franceschi, and A. Carbone
Malignant tumours in patients with HIV infection
BMJ, April 30, 1994; 308(6937): 1148 - 1153.
[Full Text]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.